Trials / Completed
CompletedNCT05959070
An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO)
Multi-Country Prospective Real-World Study to Validate the CLCI Instrument (DermCLCI-p) in Patients With Moderate-to-Severe Chronic Plaque Psoriasis (IMMagine)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 154 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The IMMagine study aims to validate the newly developed CLCI instrument (DermCLCI-p) in moderate to severe psoriasis (PsO) patients, who will be started on Risankizumb (RZB) treatment and will be enrolled into the validation study up to 28 weeks. The treatment decision for RZB must be made independent of this study enrollment.
Conditions
Timeline
- Start date
- 2023-11-09
- Primary completion
- 2025-03-21
- Completion
- 2025-03-21
- First posted
- 2023-07-25
- Last updated
- 2026-03-25
Locations
16 sites across 3 countries: Belgium, Canada, Germany
Source: ClinicalTrials.gov record NCT05959070. Inclusion in this directory is not an endorsement.